Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant camrelizumab after concurrent chemoradiotherapy for high-risk locally advanced cervical cancer
ChiCTR2000033708Phase 4Not yet recruiting
- Sponsor
- The Affiliated Hospital of Jiangnan University
- Start
- Jun 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of camrelizumab in Cervical Cancer (CC) (2 arms), sponsored by The Affiliated Hospital of Jiangnan University. Primary endpoint: Progression-free survival. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2000033708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033708.